PP01.65: Real-World Experience of Afatinib as First Line Treatment in Advanced NSCLC with Exon 19 Deletion and Exon 21 L858R Mutations as a Cheaper Alternative to Osimertinib in an LMIC Setting: A Single Institutional Study

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology Pub Date : 2026-05-01 Epub Date: 2026-05-07 DOI:10.1016/j.jtho.2026.103808

Dr. Anupam Datta , Dr. Soumita Majumder

引用次数: 0

查看原文本刊更多论文

PP01.65：一项单一机构研究：阿法替尼作为LMIC环境中奥西替尼更便宜的替代方案，在具有外显子19缺失和外显子21 L858R突变的晚期NSCLC一线治疗的实际经验

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.